Sugi Predict

Sugi Predict / Compounds / SCHEMBL4165286

SCHEMBL4165286

SCHEMBL4165286

CCOC(=O)c1[nH]c2c(Br)cccc2c1CCCOc1cccc2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 18/20 0.60
▸ BCL2 P10415 2/20 0.55
▸ ALB P02768 1/20 0.55
▸ EEF2K O00418 1/20 0.51
▸ MARK3 P27448 1/20 0.51
▸ AXL P30530 1/20 0.51
▸ BCL6 P41182 1/20 0.51
▸ NEK4 P51957 1/20 0.51
▸ PRKCD Q05655 1/20 0.51
▸ PRKAA1 Q13131 1/20 0.51
▸ CAMK2B Q13554 1/20 0.51
▸ CAMK2G Q13555 1/20 0.51
▸ CAMK2D Q13557 1/20 0.51
▸ MARK2 Q7KZI7 1/20 0.51
▸ PIM3 Q86V86 1/20 0.51
▸ HIPK2 Q9H2X6 1/20 0.51
▸ MKNK2 Q9HBH9 1/20 0.51
▸ MAP3K20 Q9NYL2 1/20 0.51
▸ MAP4K5 Q9Y4K4 1/20 0.51
▸ BCL2L1 Q07817 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4168695 0.97 MCL1 (0.59) MCL1BCL2ALBEEF2KMARK3
SCHEMBL4165028 0.96 MCL1 (0.58) MCL1BCL2ALBEEF2KMARK3
SCHEMBL4164399 0.90 MCL1 (0.49) MCL1BCL2ALBEEF2KMARK3
SCHEMBL4168113 0.89 MCL1 (0.55) MCL1BCL2ALBEEF2KMARK3
SCHEMBL19615272 0.89 MCL1 (0.60) MCL1BCL2ALBEEF2KMARK3
SCHEMBL24745357 0.88 MCL1 (0.58) MCL1BCL2ALBEEF2KMARK3
SCHEMBL30000839 0.88 MCL1 (0.58) MCL1BCL2ALBEEF2KMARK3
SCHEMBL4164110 0.88 MCL1 (0.50) MCL1BCL2ALBEEF2KMARK3
SCHEMBL22436730 0.88 MCL1 (0.55) MCL1BCL2ALBEEF2KMARK3
SCHEMBL22436876 0.88 MCL1 (0.55) MCL1BCL2ALBEEF2KMARK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117957218-A Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins 凯普托尔治疗学股份有限公司 2024-04-30 — — CN disclosed
WO-2022253713-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 — — WO disclosed
WO-2022255888-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 — — WO disclosed
US-11492358-B1 Macrocyclic indole derivatives THE BROAD INSTITUTE, INC. (US) 2022-11-08 — — US disclosed
EP-3458459-B1 MACROCYCLIC INDOLE DERIVATIVES BAYER AG (DE) 2022-04-27 — — EP disclosed
EP-3458459-B1 MACROCYCLIC INDOLE DERIVATIVES BAYER AG (DE) 2022-04-27 — — EP disclosed
CN-109715632-B Macrocyclic indole derivatives 拜尔公开股份有限公司 2021-10-26 — — CN disclosed
US-10981932-B2 Macrocyclic indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2021-04-20 — — US disclosed
US-10981932-B2 Macrocyclic indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2021-04-20 — — US disclosed
US-20200087322-A1 MACROCYCLIC INDOLE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-03-19 — — US disclosed
EP-3243814-A1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS AbbVie Inc. (US) 2017-11-15 — — EP disclosed
EP-2134684-B1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS ABBVIE INC (US) 2017-08-02 — — EP disclosed
US-9359296-B2 7-substituted indole Mcl-1 inhibitors ABBVIE INC. (US) 2016-06-07 — — US disclosed
US-20150284328-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBVIE INC (US) 2015-10-08 — — US disclosed
US-9035047-B2 7-substituted indole Mcl-1 inhibitors ABBVIE INC. (US) 2015-05-19 — — US disclosed
US-20140051683-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBVIE INC. (US) 2014-02-20 — — US disclosed
US-8445679-B2 7-substituted indole MCL-1 inhibitors ABBVIE INC. (US) 2013-05-21 — — US disclosed
EP-2134684-A2 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS Abbott Laboratories (US) 2009-12-23 — — EP disclosed
US-20090054402-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2009-02-26 — — US disclosed
WO-2008131000-A2 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2008-10-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051683-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MCL1 1/4885BCL2 14/4885ALB 3819/4885
US-11492358-B1 Macrocyclic indole derivatives CCND2, CCNT2, IDO1 MCL1 54/4885BCL2 624/4885ALB 2929/4885
US-10981932-B2 Macrocyclic indole derivatives CCND2, IDO1, CCNT2 MCL1 62/4885BCL2 701/4885ALB 2042/4885
US-20200087322-A1 MACROCYCLIC INDOLE DERIVATIVES CCND2, CCNA1, CCNT2 MCL1 56/4885BCL2 741/4885ALB 3051/4885
US-20150284328-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MCL1 1/4885BCL2 14/4885ALB 3819/4885
US-20090054402-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MCL1 1/4885BCL2 14/4885ALB 3819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.